Enanta Pharmaceuticals | ENTA - ДОЛГ





ДОЛГ Изменить Дата
AbbVie USD 67.5B 67.5B 2025-12
Amgen USD 54.6B 17M 2025-12
Anika Therapeutics USD 0 0 2025-03
Arrowhead Research USD 312.77M 53.52M 2025-12
AstraZeneca USD 33.92B 4.3B 2026-03
BioCryst Pharmaceuticals USD 828.6M 510K 2024-12
Biogen USD 6.56B 275.1M 2026-03
Bristol-Myers Squibb USD 47.14B 3.9B 2025-12
Enanta Pharmaceuticals USD 1.35M 0 2024-12
Gilead Sciences USD 24.94B 5M 2025-12
GlaxoSmithKline GBP 19.06B 1.34B 2026-03
Halozyme Therapeutics USD 2.14B 2.01M 2026-03
Heron Therapeutics USD 149.65M 157K 2024-09
Immunic USD 0 0 2024-06
Incyte USD 39.43M 982K 2026-03
Insmed USD 727.62M 275K 2026-03
Ionis Pharmaceuticals USD 2.34B 9.5M 2026-03
J&J USD 47.93B 2.14B 2025-12
Karyopharm Therapeutics USD 299.23M 35.14M 2025-12
Ligand Pharmaceuticals USD 451.49M 494K 2025-12
Merck USD 49.34B 7.97B 2025-12
Neurocrine Biosciences USD 406.2M 9.1M 2026-03
Novartis USD 47B 11.62B 2026-03
Novavax USD 233.31M 4.23M 2024-09
Pfizer USD 63.73B 231M 2026-03
PTC Therapeutics USD 286.94M 2.42B 2026-03
Roche Holding CHF 33.03B 1.41B 2025-06
Sarepta Therapeutics USD 1.04B 210.44M 2025-12
Vertex Pharmaceuticals USD 1.99B 44M 2026-03